Birth Testing for Infant HIV Diagnosis in Eswatini: Implementation Experience and Uptake Among Women Living With HIV in Manzini Region.
Adolescent
Adult
Anti-Retroviral Agents
/ therapeutic use
Eswatini
/ epidemiology
Female
HIV Infections
/ diagnosis
HIV-1
Health Plan Implementation
/ statistics & numerical data
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
/ statistics & numerical data
Male
Mothers
Neonatal Screening
/ methods
Pilot Projects
Pregnancy
Pregnancy Complications, Infectious
/ epidemiology
Young Adult
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
27
5
2020
medline:
16
7
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
HIV testing at birth of HIV-exposed infants (HEIs) may improve the identification of infants infected with HIV in utero and accelerate antiretroviral treatment (ART) initiation. ICAP at Columbia University supported implementation of a national pilot of HIV testing at birth (0-7 days) in Eswatini at 2 maternity facilities. Dried blood spot (DBS) samples from neonates of women living with HIV (WLHIV) were collected and processed at the National Molecular Reference Laboratory using polymerase chain reaction (PCR). Mothers received birth test results at community health clinics. We report data on HIV birth testing uptake and outcomes for HIV-positive infants from the initial intensive phase (October 2017-March 2018) and routine support phase (April-December 2018). During the initial intensive pilot phase, 1669 WLHIV delivered 1697 live-born HEI at 2 health facilities and 1480 (90.3%) HEI received birth testing. During the routine support phase, 2546 WLHIV delivered and 2277 (93.5%) HEI received birth testing. Overall October 2017-December 2018, 22 (0.6%) infants of 3757 receiving birth testing had a positive PCR test, 15 (68.2%) of whom were successfully traced and linked for confirmatory testing (2 infants were reported by caregivers to have negative follow-up HIV tests). Median time from birth test to receipt of results by the caregiver was 13 days (range: 8-23). Twelve (60.0%) of 20 infants confirmed to be HIV-positive started ART at median age of 17.5 days (12-43). One mother of an HIV-positive infant who was successfully traced refused ART following linkage to care and another child died after ART initiation. Three infants (15.0%) had died by the time their mothers were reached and 4 (15.0%) infants were never located. This pilot of universal birth testing in Eswatini demonstrates the feasibility of using a standard of care approach in a low resource and high burden setting. We document high uptake of testing for newborns among HIV-positive mothers and very few infants were found to be infected through birth testing.
Identifiants
pubmed: 32453193
doi: 10.1097/INF.0000000000002734
pii: 00006454-202009000-00020
pmc: PMC8317136
mid: NIHMS1681352
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e235-e241Subventions
Organisme : CGH CDC HHS
ID : U2G GH000994
Pays : United States
Organisme : PEPFAR
Pays : United States
Références
PLoS Med. 2015 Nov 03;12(11):e1001897
pubmed: 26528913
Pediatr Infect Dis J. 2017 Dec;36(12):1159-1164
pubmed: 28767616
PLoS One. 2014 Jan 24;9(1):e87028
pubmed: 24475214
AIDS. 2009 Jan 2;23(1):101-6
pubmed: 19065753
N Engl J Med. 2008 Nov 20;359(21):2233-44
pubmed: 19020325
PLoS One. 2012;7(2):e28510
pubmed: 22383946
PLoS One. 2017 Oct 10;12(10):e0184769
pubmed: 29016634
PLoS One. 2013 Nov 01;8(11):e78891
pubmed: 24282502
PLoS One. 2018 Jun 18;13(6):e0198344
pubmed: 29912987
AIDS. 2004 Jan 23;18(2):273-80
pubmed: 15075545
Pediatr Infect Dis J. 2018 Jun;37(6):559-563
pubmed: 29189609
Public Health Action. 2017 Jun 21;7(2):83-89
pubmed: 28695079
Lancet HIV. 2018 Dec;5(12):e706-e714
pubmed: 30416043
AIDS Res Treat. 2017;2017:2572594
pubmed: 29410914
J Int AIDS Soc. 2018 May;21(5):e25111
pubmed: 29852062
Lancet HIV. 2019 Jun;6(6):e373-e381
pubmed: 30987937
BMC Public Health. 2019 Jun 11;19(1):731
pubmed: 31185962
J Infect Dis. 2016 Nov 1;214(9):1319-1328
pubmed: 27540110
J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):454-462
pubmed: 27792684